ArticleInternal medicine (Tokyo, Japan)2026
Treatment with Daratumumab for Immunotactoid Glomerulopathy Associated with Plasma Cell Dyscrasia: A Report of Two Cases.
Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We herein report two cases of immunotactoid glomerulopathy (ITG) associated with multiple myeloma treated with daratumumab-based regimens. The first patient was an 81-year-old woman with severe renal insufficiency and IgAκ multiple myeloma (MM) that progressed to end-stage renal disease despite administering daratumumab-based therapy. The second patient, a 69-year-old man with smoldering MM, showed a favorable response to daratumumab-based treatment, with a resolution of nephrotic proteinuria. These cases underscore the association between hematological malignancies and ITG, while also emphasizing the need for clone-directed therapy. Although further accumulation of cases is needed, myeloma regimens, including daratumumab-based regimens, may be a beneficial treatment for ITG accompanied by plasma cell dyscrasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.